US2010150933A1PendingUtilityA1
Cytokine antagonists for neurological and neuropsychiatric disorders
Individually held — no corporate assignee on recordPriority: Feb 24, 1999Filed: Feb 26, 2010Published: Jun 17, 2010
Est. expiryFeb 24, 2019(expired)· nominal 20-yr term from priority
Inventors:Edward L. Tobinick
A61K 39/3955C07K 16/241C07K 2319/32A61P 25/24A61P 25/30A61P 25/06A61K 47/6835A61P 25/28A61P 25/18A61P 25/00A61K 38/1793A61K 2039/505A61K 47/60A61P 25/34A61K 38/20C07K 2319/30A61P 25/16A61K 47/6811A61K 9/0019
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need thereof, comprising: administering to said mammal a TNF-α inhibitor that is a monoclonal antibody which blocks TNF-α activity, thereby inhibiting TNF-α and treating said disorder.
Claims
exact text as granted — not AI-modified1 - 59 . (canceled)
60 . A method of treating a nerve disorder mediated by nucleus pulposus in a mammal in need thereof, comprising:
administering to said mammal a TNF-α inhibitor that is a monoclonal antibody which blocks TNF-α activity, thereby inhibiting TNF-α and treating said disorder.
61 . The method of claim 60 , wherein said nerve disorder presents as sciatica.
62 . The method of claim 60 , wherein said nerve disorder involves pain.
63 . The method of claim 60 , wherein said nerve disorder is caused by a herniated disc.
64 . The method of claim 60 , wherein said nerve disorder is nerve root injury.
65 . The method of claim 60 , wherein the mammal is human.
66 . The method of claim 60 , wherein said TNF-α inhibitor is administered parenterally.
67 . The method of claim 60 , wherein said TNF-α inhibitor is administered intramuscularly or subcutaneously.Join the waitlist — get patent alerts
Track US2010150933A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.